Dirkje S.
- Country
- The Netherlands
- Department
- Internal medicine
Research Overview
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
- Evaluation of CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib in HR+/HER2- Metastatic Breast Cancer: A Randomized Clinical Trial
Data & Insights
Has run more than one trial at 65 of 180 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating advanced gastrointestinal malignancies, with particular emphasis on colorectal cancer and esophagogastric cancer. Their work encompasses innovative therapeutic approaches for patients with specific genetic markers such as microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) conditions.
- Metastatic Colorectal Cancer Treatment
- Advanced Esophagogastric Cancer Management
- Targeted Immunotherapy Applications
Breast Cancer Therapeutics
The investigator focuses on developing treatment strategies for hormone receptor-positive breast cancer, particularly exploring endocrine therapy approaches. Their expertise includes investigating novel therapeutic combinations involving CDK4/6 inhibitors and managing HER2-negative breast cancer.
- Early-Stage Breast Cancer Treatment
- Metastatic Disease Management
- Endocrine Therapy Optimization
Supportive Cancer Care
The investigator addresses critical aspects of supportive care in cancer treatment, with particular attention to opioid-induced complications in advanced cancer patients. Their work includes developing preventive strategies for managing treatment-related side effects and improving patient quality of life.
- Pain Management Protocols
- Symptom Control Strategies
- Supportive Care Optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.